Reported 2 days ago
Neurocrine Biosciences, Inc. (NASDAQ:NBIX), known for developing treatments for neurological disorders, continues to gain investor confidence even after terminating a Phase 2 study on its investigational drug NBI-921352 due to lack of effectiveness. The company's pipeline includes promising products such as crinecerfont for congenital adrenal hyperplasia and NBI-1117568 for psychosis. Analysts have maintained Buy ratings and adjusted price targets upwards for the stock, highlighting its growth potential amidst recent challenges.
Source: YAHOO